Precision BioSciences, Inc.
PBGENE-DMD
Duchenne Muscular Dystrophy
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for PBGENE-DMD in Duchenne Muscular Dystrophy are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Following supportive data from at least 10 DMD patients, the company would meet with the FDA to align on a regulatory path forward.”